These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 35372112)

  • 1. Matrix Metalloproteinase 2 and 9 Enzymatic Activities are Selectively Increased in the Myocardium of Chronic Chagas Disease Cardiomyopathy Patients: Role of TIMPs.
    Baron MA; Ferreira LRP; Teixeira PC; Moretti AIS; Santos RHB; Frade AF; Kuramoto A; Debbas V; Benvenuti LA; Gaiotto FA; Bacal F; Pomerantzeff P; Chevillard C; Kalil J; Cunha-Neto E
    Front Cell Infect Microbiol; 2022; 12():836242. PubMed ID: 35372112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy.
    Thomas CV; Coker ML; Zellner JL; Handy JR; Crumbley AJ; Spinale FG
    Circulation; 1998 May; 97(17):1708-15. PubMed ID: 9591765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Altered balance between matrix gelatinases (MMP-2 and MMP-9) and their tissue inhibitors in human dilated cardiomyopathy: potential role of MMP-9 in myosin-heavy chain degradation.
    Rouet-Benzineb P; Buhler JM; Dreyfus P; Delcourt A; Dorent R; Perennec J; Crozatier B; Harf A; Lafuma C
    Eur J Heart Fail; 1999 Dec; 1(4):337-52. PubMed ID: 10937947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Galectin-3 (Gal-3) and the tissue inhibitor of matrix metalloproteinase (TIMP-2) as potential biomarkers for the clinical evolution of chronic Chagas cardiomyopathy.
    Menezes CADS; de Oliveira ALG; Barbosa ICM; de Jesus ACP; Chaves AT; Rocha MODC
    Acta Trop; 2024 Apr; 252():107153. PubMed ID: 38373528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Matrix Metalloproteinases MMP-1 and MMP-9 and Their Inhibitor TIMP-1 as Markers of Dilated Cardiomyopathy in Patients of Different Age.
    Antonov IB; Kozlov KL; Pal'tseva EM; Polyakova OV; Lin'kova NS
    Bull Exp Biol Med; 2018 Mar; 164(4):550-553. PubMed ID: 29504111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of matrix metalloproteinase expression and left ventricular function in idiopathic dilated cardiomyopathy.
    Yokoseki O; Yazaki Y; Suzuki J; Imamura H; Takenaka H; Isobe M
    Jpn Circ J; 2000 May; 64(5):352-7. PubMed ID: 10834450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Matrix metalloproteinases 2 and 9 are differentially expressed in patients with indeterminate and cardiac clinical forms of Chagas disease.
    Fares RC; Gomes Jde A; Garzoni LR; Waghabi MC; Saraiva RM; Medeiros NI; Oliveira-Prado R; Sangenis LH; Chambela Mda C; de Araújo FF; Teixeira-Carvalho A; Damásio MP; Valente VA; Ferreira KS; Sousa GR; Rocha MO; Correa-Oliveira R
    Infect Immun; 2013 Oct; 81(10):3600-8. PubMed ID: 23856618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impairment of Multiple Mitochondrial Energy Metabolism Pathways in the Heart of Chagas Disease Cardiomyopathy Patients.
    Teixeira PC; Ducret A; Langen H; Nogoceke E; Santos RHB; Silva Nunes JP; Benvenuti L; Levy D; Bydlowski SP; Bocchi EA; Kuramoto Takara A; Fiorelli AI; Stolf NA; Pomeranzeff P; Chevillard C; Kalil J; Cunha-Neto E
    Front Immunol; 2021; 12():755782. PubMed ID: 34867990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergic and antagonistic relationship between MMP-2 and MMP-9 with fibrosis and inflammation in Chagas' cardiomyopathy.
    Medeiros NI; Gomes JAS; Correa-Oliveira R
    Parasite Immunol; 2017 Aug; 39(8):. PubMed ID: 28543409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibrosis in endstage human heart failure: severe changes in collagen metabolism and MMP/TIMP profiles.
    Polyakova V; Loeffler I; Hein S; Miyagawa S; Piotrowska I; Dammer S; Risteli J; Schaper J; Kostin S
    Int J Cardiol; 2011 Aug; 151(1):18-33. PubMed ID: 20546954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased cardiac mRNA expression of matrix metalloproteinase-1 (MMP-1) and its inhibitor (TIMP-1) in DCM patients.
    Picard F; Brehm M; Fassbach M; Pelzer B; Scheuring S; Küry P; Strauer BE; Schwartzkopff B
    Clin Res Cardiol; 2006 May; 95(5):261-9. PubMed ID: 16598395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunoexpression of MMP-8, MMP-9 and TIMP-2 in dilated cardiomyopathy.
    Mitruţ R; Stepan AE; Mărgăritescu C; Andreiana BC; Kesse AM; Simionescu CE; Militaru C
    Rom J Morphol Embryol; 2019; 60(1):119-124. PubMed ID: 31263835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of matrix metalloproteinases and their inhibitors during hepatic tissue repair in the rat.
    Knittel T; Mehde M; Grundmann A; Saile B; Scharf JG; Ramadori G
    Histochem Cell Biol; 2000 Jun; 113(6):443-53. PubMed ID: 10933221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinase 1 and 2 in inflammation-induced corneal neovascularization.
    Ma DH; Chen JK; Kim WS; Hao YX; Wu HC; Tsai RJ; Hwang DG; Zhang F
    Ophthalmic Res; 2001; 33(6):353-62. PubMed ID: 11721189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Type-specific dysregulation of matrix metalloproteinases and their tissue inhibitors in end-stage heart failure patients: relationship between MMP-10 and LV remodelling.
    Wei Y; Cui C; Lainscak M; Zhang X; Li J; Huang J; Zhang H; Zheng Z; Hu S
    J Cell Mol Med; 2011 Apr; 15(4):773-82. PubMed ID: 20219015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determinants of extracellular matrix remodelling are differentially expressed in paediatric and adult dilated cardiomyopathy.
    Hsia TY; Ringewald JM; Stroud RE; Forbus GA; Bradley SM; Chung WK; Spinale FG
    Eur J Heart Fail; 2011 Mar; 13(3):271-7. PubMed ID: 21147820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myocardial remodeling in viral heart disease: possible interactions between inflammatory mediators and MMP-TIMP system.
    Pauschinger M; Chandrasekharan K; Schultheiss HP
    Heart Fail Rev; 2004 Jan; 9(1):21-31. PubMed ID: 14739765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of gelatinases (MMP-2 and MMP-9) and tissue inhibitors of metalloproteinases (TIMP-2 and TIMP-3) in the chicken ovary in relation to follicle development and atresia.
    Hrabia A; Wolak D; Kwaśniewska M; Kieronska A; Socha JK; Sechman A
    Theriogenology; 2019 Feb; 125():268-276. PubMed ID: 30481606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1, B⁺ tenascin-C and ED-A⁺ fibronectin in dilated cardiomyopathy: potential impact on disease progression and patients' prognosis.
    Franz M; Berndt A; Neri D; Galler K; Grün K; Porrmann C; Reinbothe F; Mall G; Schlattmann P; Renner A; Figulla HR; Jung C; Küthe F
    Int J Cardiol; 2013 Oct; 168(6):5344-51. PubMed ID: 23998545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiac remodelling in end stage heart failure: upregulation of matrix metalloproteinase (MMP) irrespective of the underlying disease, and evidence for a direct inhibitory effect of ACE inhibitors on MMP.
    Reinhardt D; Sigusch HH; Hensse J; Tyagi SC; Körfer R; Figulla HR
    Heart; 2002 Nov; 88(5):525-30. PubMed ID: 12381651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.